Table 2.
Immune checkpoint inhibitors
| IMMUNE CHECK POINT RECEPTOR THERAPIES | |
|---|---|
| Generation of Checkpoint Inhibitor | Location |
| First Generation | |
| CTLA-4 | T-Cell |
| Ipilimumab | |
| Tremelimumab | |
| Second Generation | |
| PD-1 | T-Cell |
| Nivolumab | |
| Pembrolizumab | |
| Cemiplimab | |
| PD-L1 | Tumor, APC |
| Avelumab | |
| Atezolizumab | |
| Durvalumab | |
| Next Generation - Inhibitory pathways | |
| LAG-3 (CD223) | T-Cell |
| IMP321 (Immuntep®) | |
| BMS-986016 | |
| LAG525 | |
| TIM-3 | T-Cell |
| MBG453 | |
| MEDI9447 | |
| TIGIT | T-Cell, NK |
| OMP-31M32 | |
| VISTA | T-Cell |
| JNJ-61610588 | |
| CA-170 | |
| B7-H3 | T-Cell |
| Enoblituzumab (MGA271) | |
| MGD009 | |
| 8H9 | |
| KIR | NK cell |
| Lirilumab | |
| IPH4102 | |
| AlaR | T-Cell |
| CPI-444 | |
| Next Generation - Stimulatory Pathways | |
| OX40 | T-Cell |
| 9B12 | |
| MOXR 0916 | |
| PF-04518600 | |
| MEDI6383 | |
| MEDI0562 | |
| INCAGN01949 | |
| GSK3174998 | |
| GITR | T-Cell |
| TRX-518 | |
| BMS-986156 | |
| AMG 228 | |
| MEDI1873 | |
| MEDI6469 | |
| MK-4166 | |
| INCAGN01876 | |
| GWN323 | |
| ICOS | T-Cell |
| JTX-2011 | |
| GSK3359609 | |
| MEDI-570 | |
| 4–1 BB | NK, T-cell |
| Utomilumab (PF-05082566) | |
| Urelumab | |
| BMS-936561 (MDX-1203) | |
| Varilumab | |
| CD27-CD70 | T-cell/APC, Tumor |
| ARGX-110 | |
| CD 40-CD40L | T-cell/APC, Tumor |
| CP-870893 | |
| APX005M | |
| ADC-1013 | |
| JNJ-64457107 | |
| SEA-CD40 | |
| RO7009789 | |
| IDO | Tumor |
| BMS-986205 | |
| Indoximod | |
| Epacadostat | |